Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meghan Murphy

Clinical Nurse Specialist, Adult Health Austin, TX Nurse Practitioner

NPI 1932304540 CMS profile 10491285

900 W. 38Th Street, Suite 110, Austin, TX 78705

Open in the dashboard

General payments

$29,454

573 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meghan Murphy of Austin, TX is reported in the CMS Open Payments database as having received $29,454 across 573 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,847 127
2024 General $3,901 143
2023 General $2,547 100
2022 General $15,533 135
2021 General $3,625 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meghan Murphy
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Meghan Murphy were reported at $3,847. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Meghan Murphy Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $3,625 $133 $48–$445 $132
2022 $15,533 $163 $57–$526 $149
2023 $2,547 $173 $64–$597 $160
2024 $3,901 $171 $54–$575 $164
2025 $3,847 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Atricure, Inc. $14,917 30 payments
  2. Abbott Laboratories $8,508 305 payments
  3. Biosense Webster, Inc. $1,686 34 payments
  4. Pfizer Inc. $1,075 67 payments
  5. E.R. Squibb & Sons, L.L.C. $773 56 payments
  6. Janssen Pharmaceuticals, Inc $770 38 payments
  7. Boston Scientific Corporation $633 8 payments
  8. Sanofi-Aventis U.S. LLC $206 9 payments
  9. CVRx, Inc. $200 2 payments
  10. Cardiva Medical, Inc. $109 3 payments
  11. Other $578 21 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,703 559 payments
  2. Travel and Lodging $11,236 9 payments
  3. Consulting Fee $3,500 4 payments
  4. Education $15 1 payment
Products named General payments · program years 2021–2025
  1. SYNERGY ABLATION SYSTEM $12,284 15 payments
  2. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $9,869 2 payments
  3. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $2,607 14 payments
  4. ATRICLIP LAA EXCLUSION SYSTEM $2,257 9 payments
  5. GALLANT Cardiac Rhythm Management $1,845 64 payments
  6. Carto 3 $1,510 32 payments
  7. GALLANT Structural Heart $1,161 36 payments
  8. GALLANT Cardiac Rhythm Management $1,099 41 payments
  9. Accent Pacemaker $894 3 payments
  10. XARELTO $770 38 payments
  11. Other $7,934 374 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

2,231

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$1,269,401

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

59.4%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 859 $937,409
Xarelto Rivaroxaban Brand 185 $196,858
Multaq Dronedarone Hcl Brand 58 $96,319
Flecainide Acetate Generic 452 $14,927
Dofetilide Generic 59 $12,467
Metoprolol Succinate Generic 218 $3,409
Sotalol Sotalol Hcl Brand 127 $2,123
Amiodarone Hcl Generic 63 $1,654
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 51 $1,201
Mexiletine Hcl Generic 15 $914

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$13,536

Medicare's payments for the services billed

Medicare patients

153

Average age 78

Services billed

198

69 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 73%
Heart failure 71%
Arthritis 47%
Chronic kidney disease 46%
Diabetes 39%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $229
$229 185 —
VYNDAQEL
  • PFIZER INC. $210
$210 — —
ELIQUIS
  • PFIZER INC. $93
  • E.R. Squibb & Sons, L.L.C. $89
$182 859 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $126
$126 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $66
$66 58 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

573 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record